Are penny stocks a must-have or a must-avoid? Well, that depends on who you ask.
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced that clinical data from its IPI-549 Phase 1/1b study was selected as a late-breaking abstract and will be presented on …
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced initial clinical and new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma.
In a research report issued today, Wedbush analyst David Nierengarten reiterated a Neutral rating on Infinity Pharma (NASDAQ:INFI) with a $15 price target, …
In a research report issued today, William Blair analyst Y Katherine Xu assigned an Outperform rating on Infinity Pharmaceuticals (NASDAQ:INFI) with a price target …